{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:32:29Z","timestamp":1793190749295,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41591-025-04119-2","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:02:12Z","timestamp":1765209732000},"page":"488-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7720-2490","authenticated-orcid":false,"given":"Jennifer M.","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francina","family":"Munell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Le Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-2510","authenticated-orcid":false,"given":"Tamaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Cances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-575X","authenticated-orcid":false,"given":"Liesbeth","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-034X","authenticated-orcid":false,"given":"Ian R.","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio M.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8416-9335","authenticated-orcid":false,"given":"Crystal M.","family":"Proud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie H.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Oskoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Visootsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6664-7892","authenticated-orcid":false,"given":"Gemma","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja","family":"Ili\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Ludo","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"4119_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth, B., Karakaya, M., Jeong Kye, M. & Mendoza-Ferreira, N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu. Rev. Genomics Hum. Genet. 21, 231\u2013261 (2020).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"4119_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes14071377","volume":"14","author":"K Aragon-Gawinska","year":"2023","unstructured":"Aragon-Gawinska, K., Mouraux, C., Dangouloff, T. & Servais, L. Spinal muscular atrophy treatment in patients identified by newborn careening: a systematic review. Genes 14, 1377 (2023).","journal-title":"Genes"},{"key":"4119_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb, S. J. & Kissel, J. T. Spinal muscular atrophy: a timely review. Arch. Neurol. 68, 979\u2013984 (2011).","journal-title":"Arch. Neurol."},{"key":"4119_CR4","unstructured":"Genentech. Evrysdi prescribing information. gene.com https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf (2025)."},{"key":"4119_CR5","unstructured":"Biogen. Spinraza prescribing information. spinraza.com https:\/\/www.spinraza.com\/content\/dam\/commercial\/spinraza\/caregiver\/en_us\/pdf\/spinraza-prescribing-information.pdf (2024)."},{"key":"4119_CR6","unstructured":"Novartis Gene Therapies, Inc. Zolgensma prescribing information. novartis.com https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/zolgensma.pdf (2025)."},{"key":"4119_CR7","unstructured":"European Medicines Agency. Zolgensma. EMA https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma (2025)."},{"key":"4119_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03399-0","volume":"19","author":"A Patel","year":"2024","unstructured":"Patel, A. et al. Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis. Orphanet J. Rare Dis. 19, 494 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"4119_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12325-022-02376-y","volume":"40","author":"D Fox","year":"2023","unstructured":"Fox, D., My To, T., Seetasith, A., Patel, A. M. & Iannaccone, S. T. Adherence and persistence to nusinersen for spinal muscular atrophy: a US claims-based analysis. Adv. Ther. 40, 903\u2013919 (2023).","journal-title":"Adv. Ther."},{"key":"4119_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","volume":"22","author":"JW Day","year":"2022","unstructured":"Day, J. W. et al. Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr. 22, 632 (2022).","journal-title":"BMC Pediatr."},{"key":"4119_CR11","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen, G. et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat. Med. 27, 1701\u20131711 (2021).","journal-title":"Nat. Med."},{"key":"4119_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/01926233221101309","volume":"50","author":"EK Meseck","year":"2022","unstructured":"Meseck, E. K. et al. Intrathecal sc-AAV9-CB-GFP: systemic distribution predominates following single-dose administration in cynomolgus macaques. Toxicol. Pathol. 50, 415\u2013431 (2022).","journal-title":"Toxicol. Pathol."},{"key":"4119_CR13","doi-asserted-by":"crossref","unstructured":"Proud, C.M. et al. Intrathecal onasemnogene abeparvovec (OAV101 IT) for patients with spinal muscular atrophy: phase 3, randomized, sham-controlled, double-blind STEER study. Nat. Med. (2025).","DOI":"10.1016\/j.jns.2025.123970"},{"key":"4119_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","volume":"27","author":"F Rouault","year":"2017","unstructured":"Rouault, F. et al. Disease impact on general well-being and therapeutic expectations of European Type II and II spinal muscular atrophy patients. Neuromuscul. Disord. 27, 428\u2013438 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"4119_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-221560","volume":"10","author":"RS Finkel","year":"2023","unstructured":"Finkel, R. S. et al. Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG). J. Neuromuscul. Dis. 10, 389\u2013404 (2023).","journal-title":"J. Neuromuscul. Dis."},{"key":"4119_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.nmd.2006.03.015","volume":"16","author":"KJ Krosschell","year":"2006","unstructured":"Krosschell, K. J. et al. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul. Disord. 16, 417\u2013426 (2006).","journal-title":"Neuromuscul. Disord."},{"key":"4119_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/mus.22040","volume":"44","author":"KJ Krosschell","year":"2011","unstructured":"Krosschell, K. J. et al. Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy. Muscle Nerve 44, 246\u2013251 (2011).","journal-title":"Muscle Nerve"},{"key":"4119_CR18","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman, A. M. et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J. Child Neurol. 26, 1499\u20131507 (2011).","journal-title":"J. Child Neurol."},{"key":"4119_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera, M. C. et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve 59, 426\u2013430 (2019).","journal-title":"Muscle Nerve"},{"key":"4119_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/BPO.0b013e31820fc522","volume":"31","author":"H Matsumoto","year":"2011","unstructured":"Matsumoto, H. et al. Development and initial validation of the assessment of caregiver experience with neuromuscular disease. J. Pediatr. Orthop. 31, 284\u2013292 (2011).","journal-title":"J. Pediatr. Orthop."},{"key":"4119_CR21","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1177\/15648265040251S106","volume":"25","author":"TM Wijnhoven","year":"2004","unstructured":"Wijnhoven, T. M. et al. Assessment of gross motor development in the WHO Multicentre Growth Reference Study. Food Nutr. Bull. 25, S37\u2013S45 (2004).","journal-title":"Food Nutr. Bull."}],"updated-by":[{"DOI":"10.1038\/s41591-026-04233-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04119-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:04:15Z","timestamp":1771783455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04119-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4119"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04119-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the Supplementary information initially published, in Supplementary Table 4, the \u201cTotal cumulative dose\u201d and \u201cDose intensity\u201d rows have each been separated into \u201cMean (SD)\u201d and \u201cMin-max\u201d rows. In the \u201cDose intensity\u201d, \u201cMin-max\u201d row, the entry in the \u201cTotal\u201d column was \u201c36\u201396\u201d but should have been \u201c0.42\u20130.88\u201d. The corrected Supplementary information is now available online.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04233-9","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04233-9","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Novartis Pharma sponsored this clinical trial. The authors declare the following competing interests. J.M.K. served as a site principal investigator for clinical trials sponsored by Novartis Gene Therapies\/Novartis Pharma and Scholar Rock and has received honoraria for serving on an advisory board for Novartis. L.L.G. has received payments for consulting from Roche; served as a member of advisory boards for Novartis; received non-financial support from Roche, Novartis and Biogen; and served as a principal investigator in clinical trials for Novartis, Genethon and PTC. C.C. has received consultancy payments from Roche; has been a non-remunerated member of advisory boards for Novartis, Roche and Pfizer; and has been a principal investigator in clinical trials for Novartis, Sarepta, Biogen, Roche and Scholar Rock. L.D.W. has received speaker and consulting fees from Novartis Gene Therapies\/Novartis Pharma, Biogen and Roche; has worked as a principal investigator of SMA studies sponsored by Novartis Gene Therapies\/Novartis Pharma, Roche, Scholar Rock and Biohaven; and has received research grants from Novartis Gene Therapies\/Novartis Pharma and Roche. She is also a member of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). I.R.W. has received honoraria for work performed with Novartis, Biogen, Roche and Pfizer. E.M.M. has received honoraria for scientific advisory boards and educational speaker fees from Biogen, Novartis, F. Hoffmann-La Roche, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Pfizer, Scholar Rock and Cytokinetics and has received research support grants from Biogen. His institution receives funding for clinical research from Biogen, Novartis, Roche and Scholar Rock. C.M.P. has served as a consultant for Novartis Gene Therapies\/Novartis Pharma, Biogen and Sarepta; served on a speaker\u2019s bureau for Novartis Gene Therapies\/Novartis Pharma and Biogen; and received research support from Novartis Gene Therapies\/Novartis Pharma, Biogen, Sarepta, PTC, CSL Behring, Scholar Rock and Catabasis. B.T.D. has served as an ad-hoc scientific advisory board member for Novartis Gene Therapies\/Novartis Pharma, Merck, Sarepta, Scholar Rock and Roche\/Genentech; as a steering committee chair\/member for Roche FIREFISH and MANATEE studies; and as a Data and Safety Monitoring Board member for argenX BV and Lexeo Therapeutics. He has no financial interests in any of these companies. B.T.D. has also received research support from the National Institutes of Health\/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, the Spinal Muscular Atrophy Foundation, Cure SMA and the Working on Walking Fund and grants from Biogen for CS11 and ASCEND studies and from Sarepta Pharmaceuticals, Novartis (Novartis Gene Therapies), PTC Therapeutics, Roche and Scholar Rock. L.H.H. is the site principal investigator for trials sponsored by Novartis, Biohaven, Vertex, Biogen and Astellas. She is also a consultant for Biohaven. F.M. has served as a consultant, scientific advisory board member and site principal investigator for trials sponsored by Novartis, Biogen and Roche. K.Y. and T.K. have no conflicts related to this work to disclose. M.O.\u2019s institution has received research support as a clinical trial site for Novartis Pharmaceuticals, Roche\/Genentech and Santhera Pharmaceuticals. W.L.v.d.P. is member of the scientific advisory board of SMA Europe and site principal investigator for trials sponsored by Biogen, Roche, Novartis, Scholar Rock, Biohaven and NMD Pharma. His employer received fees for consultancy service from these companies. J.V., G.W., A.I. and L.Y. are employees of Novartis and own stock\/other equities.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}